Ad
related to: response evaluation criteria for cancer research
Search results
Results from the WOW.Com Content Network
The World Health Organization published the first tumour response criteria in 1981. However the specification documents were unclear which led to criteria adjustments and inconsistent conclusions. In the mid-1990s, an International Working Party was created to simplify and standardize response criteria; it then published RECIST in 2000.
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment, where the compound being evaluated is an immuno-oncology drug.
PET response criteria in solid tumors (PERCIST) is a set of rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment, using positron emission tomography (PET). The criteria were published in May 2009 in the Journal of Nuclear Medicine (JNM). [1]
Ludwig Cancer Research is an ... of the response and played a role in evaluating the first ... new criteria for evaluating responses of cancer patients to ...
The response rate is the percentage of patients on whom a therapy has some defined effect; for example, the cancer shrinks or disappears after treatment. [9] When used as a clinical endpoint for trials of cancer treatments, this is often called the objective response rate (ORR).
Researchers have applied Hill’s criteria for causality in examining the evidence in several areas of epidemiology, including connections between exposures to molds and infant pulmonary hemorrhage, [14] ultraviolet B radiation, vitamin D and cancer, [15] [16] vitamin D and pregnancy and neonatal outcomes, [17] alcohol and cardiovascular ...
Cancer research organizations (2 C, 22 P) A. ... Response evaluation criteria in solid tumors; S. Save A Brain Foundation; SH-SY5Y; Sir Bobby Robson Foundation;
The Common Terminology Criteria for Adverse Events (CTCAE), [1] formerly called the Common Toxicity Criteria (CTC or NCI-CTC), are a set of criteria for the standardized classification of adverse events of drugs and treatment used in cancer therapy. The CTCAE system is a product of the US National Cancer Institute (NCI).
Ad
related to: response evaluation criteria for cancer research